Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Korro Bio (KRRO) EBITDA Margin (2019 - 2025)

Korro Bio's EBITDA Margin history spans 6 years, with the latest figure at 3873.37% for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin fell 292643.0% year-over-year to 3873.37%, compared with a TTM value of 1835.36% through Dec 2025, up 183320.0%, and an annual FY2025 reading of 1835.36%, up 183320.0% over the prior year.
  • EBITDA Margin for Q4 2025 was 3873.37% at Korro Bio, down from 1653.58% in the prior quarter.
  • The five-year high for EBITDA Margin was 7072.54% in Q1 2023, with the low at 3873.37% in Q4 2025.
  • Average EBITDA Margin over 4 years is 338.7%, with a median of 932.12% recorded in 2024.
  • Year-over-year, EBITDA Margin crashed -11291bps in 2021 and then crashed -292643bps in 2025.
  • Tracing KRRO's EBITDA Margin over 4 years: stood at 185.65% in 2021, then surged by 3910bps to 7072.54% in 2023, then tumbled by -113bps to 946.94% in 2024, then crashed by -309bps to 3873.37% in 2025.
  • Per Business Quant, the three most recent readings for KRRO's EBITDA Margin are 3873.37% (Q4 2025), 1653.58% (Q3 2025), and 1771.03% (Q2 2025).